Learn More
Invitrogen™ Mirikizumab Recombinant Monoclonal Antibody

Recombinant Monoclonal Antibody
Marca: Invitrogen™ MA559563
Descripción
For reconstitution, add sterile, distilled water to achieve a final antibody concentration of 1 mg/mL. Gently shake to solubilize the protein completely. Do not vortex. Reconstituted products should be stored at -80 °.
Mirikizumab is a humanized IgG4 monoclonal antibody that targets p19 subunit of IL-23. Currently, mirikizumab is being developed for a variety of immune diseases, including psoriasis, UC, and Crohn's disease (CD). Among them, the treatment of moderate to severe plaque psoriasis is in phase III clinical trials.
Especificaciones
| Mirikizumab Humanized | |
| Recombinant Monoclonal | |
| Unconjugated | |
| LY-3074828 | |
| Protein A | |
| RUO | |
| Human | |
| Antibody | |
| IgG4SP |
| ELISA, Flow Cytometry, Functional Assay, Surface Plasmon Resonance | |
| 1 mg/mL | |
| 25mM histidine with 8% sucrose, 0.01% Tween 80 and no preservative; pH 6.2 | |
| Human | |
| 100 μg | |
| Primary | |
| -20°C, Avoid Freeze/Thaw Cycles | |
| Lyophilized |
Al hacer clic en Enviar, acepta que Fisher Scientific se ponga en contacto con usted en relación con los comentarios que ha proporcionado en este formulario. No compartiremos su información para ningún otro fin. Toda la información de contacto proporcionada se mantendrá de acuerdo con nuestra Política de Privacidad. Política de privacidad.